Capabilities by Region: United Kingdom
Greenhill has considerable advisory experience in the United Kingdom. Our Managing Directors and professionals have advised clients on transactions involving many of the leading companies in the region and have access to a vast network of corporate relationships throughout the United Kingdom.
Greenhill established its presence in the United Kingdom in January 1998 with the opening of a London office.
For more information on Greenhill’s advisory practice in the United Kingdom and our capabilities in the region, please contact President David Wyles or Head of U.K. M&A Dean Rodrigues in our London Office.
Below we highlight a few of the transactions on which we have advised in this region:
Recent Transactions
Sort By
Clinigen Ltd’s Lamda Laboratories
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
David Brown Santasalo
Advised N4 Partners on the sale of David Brown Santasalo (DBS), UK based industrial gear manufacturer, to Stellex Capital Management
Flavor Specialty Ingredients division of IFF
Sole financial adviser to Exponent, one of the UK’s leading private equity firms, on the acquisition of IFF’s Flavor Specialty Ingredients division, a global leader in the base aromas market
Clinigen Ltd’s Proleukin
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
Kyowa Kirin International’s established medicines business
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company